Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Lexicon Pharmaceuticals Inc Market Cap
The Lexicon Pharmaceuticals Inc (LXRX) share price is expected to increase by 264.71% over the next year. This is based on calculating the average 12-month share price estimate provided by 7 stock analysts who have covered LXRX. Price targets range from $2 at the low end to $10 at the high end. The current analyst consensus for LXRX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
LXRX is a stock in Health Care which has been forecasted to be worth $6.2 as an average. On the higher end, the forecast price is $10 USD by Yasmeen Rahimi from Piper Sandler and on the lower end LXRX is forecasted to be $2 by from .
These are the latest 20 analyst ratings of LXRX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | Aug 21, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | Aug 13, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | Aug 2, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | Jul 16, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | Jun 24, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | Jun 21, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Initiates | Jun 17, 2024 |
| Joseph Stringer Needham | Hold | Reiterates | May 3, 2024 | |
Leerink Partners | Outperform | $5 | Initiates | Apr 30, 2024 |
| Joseph Stringer Needham | Hold | Reiterates | Apr 23, 2024 | |
| Joseph Stringer Needham | Hold | Reiterates | Apr 11, 2024 | |
| Yigal Nochomovitz Citigroup | Buy | $8 | Maintains | May 31, 2023 |
| Joseph Stringer Needham | Hold | Maintains | May 30, 2023 | |
| Andrew Tsai Jefferies | Hold | $3 | Initiates | Mar 7, 2023 |
Citigroup | Buy | Maintains | Nov 22, 2022 | |
| Yasmeen Rahimi Piper Sandler | Overweight | $10 | Initiates | Aug 12, 2022 |
| Yigal Nochomovitz Citigroup | Buy | $20 | Maintains | Jul 1, 2022 |
JP Morgan | Neutral | Upgrade | Jan 29, 2021 | |
| Liana Moussatos Wedbush | Neutral | $8 | Downgrade | Jan 29, 2021 |
| Yigal Nochomovitz Citigroup | Buy | $6 | Upgrade | Dec 8, 2020 |
When did it IPO
N/A
Staff Count
285
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Michael Exton Ph.D.
Market Cap
$621.8M
In 2023, LXRX generated $1.2M in revenue, which was a increase of 766.19% from the previous year. This can be seen as a signal that LXRX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 03 Nov 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8th, 2023 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss the financial results and to provide a business update.
Thu, 02 Nov 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentation
Wed, 01 Nov 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023
Tue, 31 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Matthew Cullen Joins as Vice President of Value and Access Lisa DeFrancesco Joins as Head of Investor Relations and Corporate Strategy THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join asu00a0head of investor relations and corporate strategy, effective November 13, 2023. Mr. Cullen brings Lexicon more than 35 years of industry experience in market access and sales leadership.
Mon, 30 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Presentations from four Lexicon-sponsored studies will highlight data supporting current and potential future use of sotagliflozin
Tue, 17 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Abstracts for cost-effectiveness data and budget-impact model published in the Journal of Managed Care & Specialty Pharmacy (JMCP)
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
